Benzinga
21 May 2026, 18:11 UTC · 24w ago
BioMarin Reveals Dwarfism Study Data, Stock Soars
Impact · against what's priced in
BioMarin (BMRN) is a strong buy on the positive Phase 3 results for VOXZOGO in hypochondroplasia and the label expansion for Palynziq, both of which expand its addressable market. The data for VOXZOGO is particularly material as it targets a condition with no currently approved therapies.
- BMRN+0.80
No priced-in read yet
- In context
The Phase 3 CANOPY-HCH-3 study met its primary endpoint with a 2.33 cm/year growth increase, and the Palynziq label expansion to adolescents aged 12+ both provide immediate catalysts for revenue growth.
Read from the article alone
Search tags
